Rytmonorm is indicated for the prophylaxis and treament of ventricular arrhythmias.
Rytmonorm is also indicated for the prophylaxis and treatment of paroxysmal supraventricular tachyarrhythmias which include paroxysmal atrial flutter/fibrillation and paroxysmal re-entrant tachycardias involving the AV node or accessory bypass tracts, when standard therapy has failed or is contra-indicated.
Posology and method of administration
It is recommended that Rytmonorm therapy should be initiated under hospital conditions, by a physician experienced in the treatment of arrhythmias.
The individual maintenance dose should be determined under cardiological surveillance including ECG monitoring and blood pressure control. If the QRS interval is prolonged by more than 20%, the dose should be reduced or discontinued until the ECG returns to normal limits.
Adults: Initially, 150 mg three times daily increasing at a minimum of three-day intervals to 300 mg twice daily and if necessary, to a maximum of 300 mg three times daily. Dose increases should not be attempted until the patient has been receiving treatment for three to four days.
The tablets should be swallowed whole and taken with a drink after food.
A reduction in the total daily dose is recommended for patients below 70 kg body weight.
Elderly: No overall differences in safety or effectiveness were observed in this patient population, but greater sensitivity of some older individuals cannot be ruled out, therefore, these patients should be carefully monitored.
Treatment should be initiated gradually and with particular caution in small incremental doses. The same applies to maintenance therapy. Any dose increases that may be required should not be undertaken until after five to eight days of therapy.
Children: A suitable dosage form of Rytmonorm for children is not available.
Hepatic/Renal Impairment: In patients whose liver and/or kidney function is impaired, there may be drug accumulation after standard therapeutic doses.
Nonetheless, patients with these conditions can still be titrated on propafenone hydrochloride under ECG and plasma level monitoring.
Rytmonorm® Side Effects
- Anxiety
- Sleep disorders
Dizziness - Cardiac conduction disorders
- Palpitaions
- Headache
- Dysgeusia
- Vision blurred
- Bradycardia
- Atrial flutter
- Dyspnoea
- Abdominal pain
- Vomiting & Nausea
- Diarrhoea or Constipation
- Dry mouth
- abnormal hepatic function.
Rytmonorm® – PIL
You can read Rytmonorm Patient Information Leaflet from the link here.
For Arabic information about Rytomonorm – click the link here
Rytmonorm® in Egypt
- Manufactured by Kahira Pharma. & Chem.Ind.Co.
- Market Authorization Holder in Egypt: Abbott Laboratories GmbH – Freundallee 9A,30173 Hannover – Germany.
- License Holder in Country of origin: Mylan Healthcare GmbH-Freundalleere 9A,30173 Hannover Germany.
Product reference code: C01BC03.